Search

Your search keyword '"Pastorello E"' showing total 103 results
Start Over Author "Pastorello E" Search Limiters Full Text
103 results on '"Pastorello E"'

1. Toxicity patterns and preliminary clinical outcomes of 1.5T MR-guided stereotactic body radiotherapy for prostate cancer

Author

Cuccia, F., primary, Figlia, V., additional, Rigo, M., additional, Mazzola, R., additional, Giaj Levra, N., additional, Nicosia, L., additional, Ricchetti, F., additional, Trapani, G., additional, Attinà, G., additional, Pastorello, E., additional, Vitale, C., additional, Ruggieri, R., additional, and Alongi, F., additional

Published
2022
Full Text
View/download PDF

4. Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma

Author

Sposato B., Scalese M., Ricci A., Rogliani P., Paggiaro P., Migliorini M. G., Di Tomassi M., Olivieri C., Perrella A., Camiciottoli G., Maselli R., Pelaia G., Busceti M. T., Sabato E., Cagnazzo M. G., Colombo F., Palumbo L., Ravazzi A., Bucca C., Caiaffa M. F., Berra A., Calabrese C., Stanziola A. A., Schino P., Di Gioacchino M., Cazzola M., Segreti A., Pastorello E. A., Scibilia G., Vianello A., Marchi M. R., Paladini L., Baglioni S., Abbritti M., Almerigogna F., Matucci A., Vultaggio A., Maggi E., Maestrelli P., Guarnieri G., Steinhilber G., Bonavia M., Rottoli P., Bargagli E., Senna G., Caminati M., Macchia L., Bellia V., Scichilone N., Novelli F., Latorre M., Vergura L., Masieri S., Rosati Y., Milanese M., Folletti I., Pio R., Pio A., Maccari U., Maggiorelli C., Scala R., Vignale L., Pulera N., Carpagnano G. E., Foschino Barbaro M. P., Sposato B., Scalese M., Ricci A., Rogliani P., Paggiaro P., Migliorini M.G., Di Tomassi M., Olivieri C., Perrella A., Camiciottoli G., Maselli R., Pelaia G., Busceti M.T., Sabato E., Cagnazzo M.G., Colombo F., Palumbo L., Ravazzi A., Bucca C., Caiaffa M.F., Berra A., Calabrese C., Stanziola A.A., Schino P., Di Gioacchino M., Cazzola M., Segreti A., Pastorello E.A., Scibilia G., Vianello A., Marchi M.R., Paladini L., Baglioni S., Abbritti M., Almerigogna F., Matucci A., Vultaggio A., Maggi E., Maestrelli P., Guarnieri G., Steinhilber G., Bonavia M., Rottoli P., Bargagli E., Senna G., Caminati M., Macchia L., Bellia V., Scichilone N., Novelli F., Latorre M., Vergura L., Masieri S., Rosati Y., Milanese M., Folletti I., Pio R., Pio A., Maccari U., Maggiorelli C., Scala R., Vignale L., Pulera N., Carpagnano G.E., Foschino Barbaro M.P., Sposato, B., Scalese, M., Ricci, A., Rogliani, P., Paggiaro, P., Migliorini, M. G., Di Tomassi, M., Olivieri, C., Perrella, A., Camiciottoli, G., Maselli, R., Pelaia, G., Busceti, M. T., Sabato, E., Cagnazzo, M. G., Colombo, F., Palumbo, L., Ravazzi, A., Bucca, C., Caiaffa, M. F., Berra, A., Calabrese, C., Stanziola, A. A., Schino, P., Di Gioacchino, M., Cazzola, M., Segreti, A., Pastorello, E. A., Scibilia, G., Vianello, A., Marchi, M. R., Paladini, L., Baglioni, S., Abbritti, M., Almerigogna, F., Matucci, A., Vultaggio, A., Maggi, E., Maestrelli, P., Guarnieri, G., Steinhilber, G., Bonavia, M., Rottoli, P., Bargagli, E., Senna, G., Caminati, M., Macchia, L., Bellia, V., Scichilone, N., Novelli, F., Latorre, M., Vergura, L., Masieri, S., Rosati, Y., Milanese, M., Folletti, I., Pio, R., Pio, A., Maccari, U., Maggiorelli, C., Scala, R., Vignale, L., Pulera, N., Carpagnano, G. E., Foschino Barbaro, M. P., and Et, Al

Subjects
Pulmonary and Respiratory Medicine, severe asthma, medicine.medical_specialty, medicine.drug_class, Severe asthma, Eosinophil, Settore MED/10 - Malattie Dell'Apparato Respiratorio, Gastroenterology, Persistence (computer science), 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Bronchodilator, allergic asthma, blood eosinophil, bronchodilator reversibility, lung function decline, severe asthma, salbutamol, Forced Expiratory Volume, medicine, Settore MED/10, Immunology and Allergy, Humans, 030212 general & internal medicine, Blood eosinophil, Lung, Genetics (clinical), Lung function, Bronchodilator Agent, allergic asthma, blood eosinophil, bronchodilator reversibility, lung function decline, salbutamol, bronchodilator agents, eosinophils, forced expiratory volume, humans, lung, airway obstruction, asthma, business.industry, Airway obstruction, medicine.disease, Asthma, Bronchodilator Agents, Airway Obstruction, Eosinophils, 030228 respiratory system, Salbutamol, Blood eosinophils, business, medicine.drug, Human
Abstract

Objective: This study analysed whether the persistence of both reversible airway obstruction (RAO) and elevated BE counts was associated to reduced asthma control and accelerated lung function decline in treated severe asthmatics. Methods: About 202 severe asthmatics were studied after 12–120months of step-5 treatment associated to anti-IgE therapy. Following treatments, reversibility tests, after inhaling 400 mcg of Salbutamol, were performed. FEV1>12% or ≤12% changes differentiated RAO+ from RAO− subjects. Blood eosinophil (BE) counts after treatment were considered. Results: Pre-/post-treatment bronchodilator FEV1% and ACT were lower (61% [50–71], 74.4% [62.5–83.7] and 20[18–22]), whereas BE were higher (380 cells/µl [170–590]) in RAO+ compared to RAO− subjects (77% [64–88], p=0.0001, 81.8% [66.1–94.3], p=0.0001, 21[18–23], p=0.045 and 230 cells/µl [80–360], p=0.003). A negative relationship between SABA-induced FEV1% changes and pre-bronchodilator FEV1% (β=−0.551%; p=0.0001) and ACT (β=−0.059; p=0.038) was found. Conversely, post-treatment BE levels were positively related (β=145.565 cells/µl; p=0.003) to FEV1>12% increases. A rising trend of pre-/post-bronchodilator FEV1% in time was observed in RAO− subjects with BE300 cells/µl reaching lower values after more than 36months of step-5 treatment (59.6% [39.9–72.1] vs 74[66.5–89.2] of RAO+ individuals with BE300 cells/µl [p=0.009]). Conclusion: Persistent SABA-induced FEV1>12%, especially when associated to BE>300 cells/ml, may be a marker of accelerated lung function decline in severe asthmatics despite maximal step-5 treatment. The highest bronchodilation associated to the lowest BE levels should be the main goal of asthma treatment to prevent such decline.

Published
2020

5. PSMA-guided SBRT for bone oligometastatic prostate cancer: a monoinstitutional report of preliminary outcomes and toxicity

Author

Cuccia, F., primary, Mazzola, R., additional, Pastorello, E., additional, Rigo, M., additional, Giaj-Levra, N., additional, Nicosia, L., additional, Figlia, V., additional, Ricchetti, F., additional, Attinà, G., additional, Vitale, C., additional, De Simone, A., additional, Gurrera, D., additional, Naccarato, S., additional, Sicignano, G., additional, Ruggieri, R., additional, and Alongi, F., additional

Published
2021
Full Text
View/download PDF

6. Preliminary report of toxicity and quality of life of the first 100 patients treated with 1.5T MR-guided stereotactic body radiotherapy for prostate cancer

Author

Cuccia, F., primary, Figlia, V., additional, Rigo, M., additional, Nicosia, L., additional, Mazzola, R., additional, Giaj-Levra, N., additional, Ricchetti, F., additional, Attinà, G., additional, Pastorello, E., additional, De Simone, A., additional, Gurrera, D., additional, Naccarato, S., additional, Sicignano, G., additional, Ruggieri, R., additional, and Alongi, F., additional

Published
2021
Full Text
View/download PDF

7. Impact of hydrogel peri-rectal spacer insertion on seminal vesicles intra-fraction motion during 1.5 t-MRI-guided adaptive stereotactic body radiotherapy for localized prostate cancer

Author

Cuccia, F., primary, Mazzola, R., additional, Sicignano, G., additional, Vitale, C., additional, Rigo, M., additional, Giaj-Levra, N., additional, Nicosia, L., additional, Figlia, V., additional, Ricchetti, F., additional, Attinà, G., additional, Pastorello, E., additional, De Simone, A., additional, Gurrera, D., additional, Naccarato, S., additional, Ruggieri, R., additional, and Alongi, F., additional

Published
2021
Full Text
View/download PDF

9. The diagnosis and management of allergic reactions in patients sensitized to non-specific lipid transfer proteins

Author

Skypala, I.J. Bartra, J. Ebo, D.G. Antje Faber, M. Fernández-Rivas, M. Gomez, F. Luengo, O. Till, S.J. Asero, R. Barber, D. Cecchi, L. Diaz Perales, A. Hoffmann-Sommergruber, K. Anna Pastorello, E. Swoboda, I. Konstantinopoulos, A.P. van Ree, R. Scala, E. European Academy of Allergy & Clinical Immunology (EAACI) Task Force: Non-specific Lipid Transfer Protein Allergy Across Europe

Abstract

Sensitization to one or more non-specific lipid transfer proteins (nsLTPs), initially thought to exist mainly in southern Europe, is becoming accepted as a cause of allergic reactions to plant foods across Europe and beyond. The peach nsLTP allergen Pru p 3 is a dominant sensitizing allergen and peaches a common food trigger, although multiple foods can be involved. A frequent feature of reactions is the requirement for a cofactor (exercise, alcohol, non-steroidal anti-inflammatory drugs, Cannabis sativa) to be present for a food to elicit a reaction. The variability in the food and cofactor triggers makes it essential to include an allergy-focused diet and clinical history in the diagnostic workup. Testing on suspected food triggers should also establish whether sensitization to nsLTP is present, using purified or recombinant nsLTP allergens such as Pru p 3. The avoidance of known trigger foods and advice on cofactors is currently the main management for this condition. Studies on immunotherapy are promising, but it is unknown whether such treatments will be useful in populations where Pru p 3 is not the primary sensitizing allergen. Future research should focus on the mechanisms of cofactors, improving diagnostic accuracy and establishing the efficacy of immunotherapy. © 2021 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Published
2021

10. Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes

Author

Sposato, B, Scalese, M, Milanese, M, Masieri, S, Cavaliere, C, Latorre, M, Scichilone, N, Ricci, A, Cresti, A, Santus, P, Olivieri, C, Perrella, A, Rogliani, P, Paggiaro, P, Migliorini, M. G, Di Tomassi, M, Camiciottoli, G, Maselli, R, Pelaia, G, Busceti, M. T, Sabato, E, Cagnazzo, M. G, Colombo, F, Palumbo, L, Ravazzi, A, Bucca, C, Caiaffa, M. F, Berra, A, Calabrese, C, Stanziola, A. A, Schino, P, Di Gioacchino, M, Cazzola, M, Segreti, A, Pastorello, E. A, Scibilia, G, Vianello, A, Marchi, M. R, Paladini, L, Baglioni, S, Abbritti, M, Almerigogna, F, Matucci, A, Vultaggio, A, Maggi, E, Maestrelli, P, Guarnieri, G, Steinhilber, G, Bonavia, M, Rottoli, P, Bargagli, E, Senna, G, Caminati, M, Macchia, L, Bellia, V, Novelli, F, Vergura, L, Rosati, Y, Folletti, I, Pio, R, Pio, A, Maccari, U, Maggiorelli, C, Scala, R, Vignale, L, Pulerà, N, Carpagnano, G. E, Foschino Barbaro, M. P, The Omalizumab Italian Study Group, Sposato, B, Scalese, M, Milanese, M, Masieri, S., Cavaliere, C, Latorre, M., Scichilone, N., Ricci, A., Cresti, A., Santus, P., Olivieri, C., Perrella, A., Rogliani, P., Paggiaro, P., Sposato, B., Migliorini, M. G., Di Tomassi, M., Camiciottoli, G., Maselli, R., Pelaia, G., Busceti, M. T., Sabato, E., Cagnazzo, M. G., Colombo, F., Palumbo, L., Ravazzi, A., Bucca, C., Caiaffa, M. F., Berra, A., Calabrese, C., Stanziola, A. A., Schino, P., Di Gioacchino, M., Cazzola, M., Segreti, A., Pastorello, E. A., Scibilia, G., Vianello, A., Marchi, M. R., Paladini, L., Baglioni, S., Abbritti, M., Almerigogna, F., Matucci, A., Vultaggio, A., Maggi, E., Maestrelli, P., Guarnieri, G., Steinhilber, G., Bonavia, M., Rottoli, P., Bargagli, E., Senna, G., Caminati, M., Macchia, L., Bellia, V., Novelli, F., Vergura, L., Scalese, M., Rosati, Y., Milanese, M., Folletti, I., Pio, R., Pio, A., Maccari, U., Maggiorelli, C., Scala, R., Vignale, L., Pulera, N., Carpagnano, G. E., Foschino Barbaro, M. P., Cavaliere, C., Sposato B., Scalese M., Milanese M., Masieri S., Cavaliere C., Latorre M., Scichilone N., Ricci A., Cresti A., Santus P., Olivieri C., Perrella A., Rogliani P., Paggiaro P., Migliorini M.G., Di Tomassi M., Camiciottoli G., Maselli R., Pelaia G., Busceti M.T., Sabato E., Cagnazzo M.G., Colombo F., Palumbo L., Ravazzi A., Bucca C., Caiaffa M.F., Berra A., Calabrese C., Stanziola A.A., Schino P., Di Gioacchino M., Cazzola M., Segreti A., Pastorello E.A., Scibilia G., Vianello A., Marchi M.R., Paladini L., Baglioni S., Abbritti M., Almerigogna F., Matucci A., Vultaggio A., Maggi E., Maestrelli P., Guarnieri G., Steinhilber G., Bonavia M., Rottoli P., Bargagli E., Senna G., Caminati M., Macchia L., Bellia V., Novelli F., Vergura L., Rosati Y., Folletti I., Pio R., Pio A., Maccari U., Maggiorelli C., Scala R., Vignale L., Pulera N., Carpagnano G.E., and Foschino Barbaro M.P.

Subjects
Adult, Male, medicine.medical_specialty, Settore MED/09 - Medicina Interna, Treatment outcome, MEDLINE, Omalizumab, Settore MED/10 - Malattie Dell'Apparato Respiratorio, Immunoglobulin E, eosinophil, Omalizumab, anti-IgE, asthma, Leukocyte Count, Text mining, Forced Expiratory Volume, Internal medicine, Eosinophilia, medicine, Humans, Immunology and Allergy, Anti-Asthmatic Agents, Blood eosinophil, Aged, Retrospective Studies, Asthma, biology, business.industry, Retrospective cohort study, Middle Aged, asthma, Prognosis, medicine.disease, Eosinophils, Treatment Outcome, inflammation, biology.protein, Female, business, medicine.drug
Published
2019

11. Detection of Gibberellin-Regulated Protein (Peamaclein) Sensitization among Italian Cypress Pollen-Sensitized Patients

Author

Asero, R, Abbadessa, S, Aruanno, A, Barilaro, G, Barzaghi, C, Bignardi, D, Bilò, M B, Borro, M, Bresciani, M, Busa, M, Buzzulini, F, Cavaliere, C, Cecchi, L, Ciccarelli, A, Cortellini, G, Cucinelli, F, Deleonardi, G, Emiliani, F, Farsi, A, Ferrarini, E, Franchini, M, Ingrassia, A, Lippolis, D, Losappio, L, Marra, A M, Martini, M, Masieri, S, Mauro, M, Mazzolini, M, Muratore, L, Murzilli, F, Nucera, E, Pastorello, E A, Pinter, E, Polillo, B R, Pravettoni, V, Quercia, O, Rizzi, A, Russello, M, Sacerdoti, C, Scala, E, Scala, G, Scarpa, A, Schroeder, J, Uasuf, G G, Villalta, D, Yang, B, Mistrello, G, Amato, S, Lidholm, J, Nucera, E (ORCID:0000-0002-0565-7680), Rizzi, A (ORCID:0000-0002-6795-746X), Asero, R, Abbadessa, S, Aruanno, A, Barilaro, G, Barzaghi, C, Bignardi, D, Bilò, M B, Borro, M, Bresciani, M, Busa, M, Buzzulini, F, Cavaliere, C, Cecchi, L, Ciccarelli, A, Cortellini, G, Cucinelli, F, Deleonardi, G, Emiliani, F, Farsi, A, Ferrarini, E, Franchini, M, Ingrassia, A, Lippolis, D, Losappio, L, Marra, A M, Martini, M, Masieri, S, Mauro, M, Mazzolini, M, Muratore, L, Murzilli, F, Nucera, E, Pastorello, E A, Pinter, E, Polillo, B R, Pravettoni, V, Quercia, O, Rizzi, A, Russello, M, Sacerdoti, C, Scala, E, Scala, G, Scarpa, A, Schroeder, J, Uasuf, G G, Villalta, D, Yang, B, Mistrello, G, Amato, S, Lidholm, J, Nucera, E (ORCID:0000-0002-0565-7680), and Rizzi, A (ORCID:0000-0002-6795-746X)

Abstract

Background: Peach gibberellin-regulated protein (peamaclein) has recently emerged as a relevant food allergen in cypress pollen-hypersensitive patients. Objective: We looked for mono-sensitization to peamaclein among Italian cypress-pollen allergic patients. Material and methods: 835 cypress pollen hypersensitive patients from 28 Italian allergy centers under went thorough interview for food-allergic reactions, and SPT with a commercial peach extracts containing peamaclein. In peach reactors, IgE to rPru p 3 was measured, and those scoring negative were enrolled as potentially mono-sensitized to peamaclein. IgE reactivity to rPru p 7 was evaluated by immunoblot and by an experimental ImmunoCAP with rPru p 7. Results: Peach SPT scored positive in 163 (19.5%) patients but 127 (77,9%) were excluded because Pru p 3 reactors. Twenty-four (14,7%, corresponding to 2.8% of the entire study population) were considered as potentially mono-sensitized to peamaclein. Their distribution did not show any geographic preference. Seventeen/24 (70,8%) had a history of food allergy, in most cases (n=15) to peach. Other offending foods included other Rosaceae, citrus fruits, fig, melon, tree nuts, and kiwi. On peach immunoblot, only 3/18 putative peamaclein allergic subjects reacted to a band at about 7kDa; 4 other patients reacted at about 50-60 kDa. Ten/18 (56%) scored positive for Pru p 7 on ImmunoCAP. Conclusion: Peamaclein allergy and sensitization prevalence seem rare in Italy. Most patients react to peach, albeit other Rosaceae fruits and several citrus fruits may also act as offending foods. Peach and cypress pollen probably share also cross-reacting allergens other than peamaclein.

Published
2020

12. Evaluation of two commercial peach extracts for skin prick testing in the diagnosis of hypersensitivity to lipid transfer protein. A multicenter study

Author

Asero, R, Aruanno, A, Bresciani, Marco Torkel, Brusca, I, Carollo, M, Cecchi, L, Cortellini, G, Deleonardi, G, Farsi, A, Ferrarini, E, Gabrielli, Francesca Augusta, Ingrassia, A, Mauro, M, Murzilli, F, Nucera, Eleonora, Onida, R, Pastorello, E A, Pinter, E, Rizzi, Angela, Russello, M, Sacerdoti, C, Scala, G, Villalta, D, Zampogna, S, Amato, S, Mistrello, G, Scala, E, Bresciani, M, Gabrielli, G, Nucera, E (ORCID:0000-0002-0565-7680), Rizzi, A (ORCID:0000-0002-6795-746X), Asero, R, Aruanno, A, Bresciani, Marco Torkel, Brusca, I, Carollo, M, Cecchi, L, Cortellini, G, Deleonardi, G, Farsi, A, Ferrarini, E, Gabrielli, Francesca Augusta, Ingrassia, A, Mauro, M, Murzilli, F, Nucera, Eleonora, Onida, R, Pastorello, E A, Pinter, E, Rizzi, Angela, Russello, M, Sacerdoti, C, Scala, G, Villalta, D, Zampogna, S, Amato, S, Mistrello, G, Scala, E, Bresciani, M, Gabrielli, G, Nucera, E (ORCID:0000-0002-0565-7680), and Rizzi, A (ORCID:0000-0002-6795-746X)

Abstract

The clinical usefulness of two commercial peach extracts for SPT (by Lofarma SpA and ALK-Abellò, respectively) was compared in a multicenter study carried out in Italy. Peach allergic patients were tested with the two extracts in parallel and underwent the detection of IgE specific for all three peach allergens currently available (Pru p 1, Pru p 3, and Pru p4, respectively). The two extracts were almost identical in terms of sensitivity and specificity, being able to detect virtually all patients sensitized to stable peach allergens (lipid transfer protein [LTP] and, presumably, peamaclein) but scoring negative in patients exclusively sensitive to labile allergens (either PR-10 and/or profilin). Thus, the two extracts represent an excellent tool to carry out a preliminary component-resolved diagnosis of peach allergy at the first patient visit

Published
2020

15. Clinical approach on challenge and desensitization procedures with aspirin in patients with ischemic heart disease and nonsteroidal anti-inflammatory drug hypersensitivity

Author

Cortellini, G, Romano, A, Santucci, A, Barbaud, A, Bavbek, S, Bignardi, D, Blanca, M, Bonadonna, P, Costantino, M T, Laguna, J J, Lombardo, C, Losappio, L M, Makowska, J, Nakonechna, A, Quercia, O, Pastorello, E A, Patella, V, Terreehorst, I, Testi, S, Cernadas, J R, EAACI Drug Interest Group on Challenge and Desensitization Procedures with Aspirin in CAD, Dionicio Elera, J, Lippolis, D, Voltolini, S, Grosseto, D, Paediatric Pulmonology, Ear, Nose and Throat, and Amsterdam Cardiovascular Sciences

Subjects
Male, Acute coronary syndrome, Allergy, aspirin, medicine.medical_treatment, Immunology, Clinical Decision-Making, Myocardial Ischemia, challenge procedure, Comorbidity, 030204 cardiovascular system & hematology, nonsteroidal anti-inflammatory drugs hypersensitivity, Bronchospasm, Coronary artery disease, Drug Hypersensitivity, 03 medical and health sciences, 0302 clinical medicine, medicine, Immunology and Allergy, Humans, Desensitization (medicine), Aged, Aspirin, Angioedema, business.industry, Settore MED/09 - MEDICINA INTERNA, Anti-Inflammatory Agents, Non-Steroidal, Middle Aged, medicine.disease, desensitization procedure, Treatment Outcome, 030228 respiratory system, Desensitization, Immunologic, Anesthesia, Female, medicine.symptom, business, Anaphylaxis, Algorithms, medicine.drug
Abstract

Background Hypersensitivity to acetylsalicylic acid (ASA) constitutes a serious problem for subjects with coronary artery disease. In such subjects, physicians have to choose the more appropriate procedure between challenge and desensitization. As the literature on this issue is sparse, the present study aims to establish in these subjects clinical criteria for eligibility for an ASA challenge and/or desensitization. Methods Collection and analysis of data on ASA challenges and desensitizations from 10 allergy centers, as well as consensus among the related physicians and an expert panel. Results Altogether, 310 subjects were assessed; 217 had histories of urticaria/angioedema, 50 of anaphylaxis, 26 of non-immediate cutaneous eruptions, and 17 of bronchospasm related to ASA/NSAID intake. Specifically, 119 subjects had index reactions to ASA doses lower than 300 mg. Of the 310 subjects, 138 had an acute coronary syndrome (ACS), 101 of whom underwent desensitizations, whereas 172 suffered from a chronic ischemic heart disease (CIHD), 126 of whom underwent challenges. Overall, 163 subjects underwent challenges and 147 desensitizations; 86 of the latter had index reactions to ASA doses of 300 mg or less. Ten subjects reacted to challenges, 7 at doses up to 500 mg, 3 at a cumulative dose of 110 mg. The desensitization failure rate was 1.4%. Conclusions In patients with stable CIHD and histories of non-severe hypersensitivity reactions to ASA/NSAIDs, an ASA challenge is advisable. Patients with an ACS and histories of hypersensitivity reactions to ASA, especially following doses lower than 100 mg, should directly undergo desensitization. This article is protected by copyright. All rights reserved.

Published
2017

18. Anti-Neutrophil Cytoplasmic Antibodies Positivity and Anti-Leukotrienes in Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Monocentric Study on 134 Italian Patients

Author

Schroeder, J, Folci, M, Losappio, L, Chevallard, M, Sinico, R, Mirone, C, De Luca, F, Nichelatti, M, Pastorello, E, Schroeder, Jan Walter, Folci, Marco, Losappio, Laura Michelina, Chevallard, Michel, Sinico, Renato Alberto, Mirone, Corrado, De Luca, Fabrizio, Nichelatti, Michele, Pastorello, Elide Anna, Schroeder, J, Folci, M, Losappio, L, Chevallard, M, Sinico, R, Mirone, C, De Luca, F, Nichelatti, M, Pastorello, E, Schroeder, Jan Walter, Folci, Marco, Losappio, Laura Michelina, Chevallard, Michel, Sinico, Renato Alberto, Mirone, Corrado, De Luca, Fabrizio, Nichelatti, Michele, and Pastorello, Elide Anna

Abstract

Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis associated with asthma, anti-neutrophil cytoplasmic antibodies (ANCA) positivity, and tissue eosinophilia. Objective: To describe the presenting clinical features, significant biochemical alterations, and also potential pathogenic factors in adult patients diagnosed in our Center over a period of >20 years. Method: A retrospective study of EGPA patients diagnosed from 1994 to 2019 at ASST Grande Ospedale Metropolitano Niguarda Ca' Granda, Milan (Italy), which was performed according to the 1990 American College of Rheumatology criteria and Chapel Hill Consensus Conference definition. A dataset was compiled, registering demographic and clinical features, biochemical analysis at onset, and also the therapies received 3 months prior to EGPA diagnose. Statistical analyses were subsequently conducted dividing patients in 2 groups based on ANCA positivity and comparing them. Results: Two groups were clearly identified by ANCA serology and specific organ involvement in accordance with literature reports; however, our data underline for the first time the association between anti-leukotriene receptor antagonists (LTRAs) and ANCA positivity. The group of previously treated patients presents an OR of 6.42 to be ANCA positive. This finding could be attributed to an imbalanced stimulation of leukotriene receptors, inducing both mast cells activation and an increased neutrophil extracellular traps release from neutrophils. Conclusion: Despite the limitations of this retrospective study, the association between LTRAs and ANCA antibodies elucidates the mechanism by which innate immunity is directly involved in tolerance breakdown and autoantibodies production. Validation of our results with targeted studies could clarify the differences between ANCA-positive and ANCA-negative patients with important consequences on the use of some drug classes in the treatment of EGPA and asthmatic subjects.

Published
2019

19. House dust mite allergy and shrimp allergy: a complex interaction

Author

Celi, G, Brusca, I, Scala, E, Villalta, D, Pastorello, E, Farioli, L, Cortellini, G, Deleonardi, G, Galati, P, Losappio, L, Manzotti, G, Pirovano, B, Muratore, L, Murzilli, F, Cucinelli, F, Musarra, Teresa, Cilia, M, Nucera, Eleonora, Aruanno, A, Ria, Francesco, Patria, M F, Varin, E, Polillo, B R, Sargentini, V, Quercia, O, Uasuf, C G, Zampogna, S, Carollo, M, Graci, S, Asero, R, Musarra, A, Nucera, E (ORCID:0000-0002-0565-7680), Ria, F (ORCID:0000-0002-8444-0307), Celi, G, Brusca, I, Scala, E, Villalta, D, Pastorello, E, Farioli, L, Cortellini, G, Deleonardi, G, Galati, P, Losappio, L, Manzotti, G, Pirovano, B, Muratore, L, Murzilli, F, Cucinelli, F, Musarra, Teresa, Cilia, M, Nucera, Eleonora, Aruanno, A, Ria, Francesco, Patria, M F, Varin, E, Polillo, B R, Sargentini, V, Quercia, O, Uasuf, C G, Zampogna, S, Carollo, M, Graci, S, Asero, R, Musarra, A, Nucera, E (ORCID:0000-0002-0565-7680), and Ria, F (ORCID:0000-0002-8444-0307)

Abstract

Summary:Background and Objective. Sensitization and allergy to shrimp among Italian house dust mite allergic patients are not well defined and were investigated in a large multicenter study. Methods. Shrimp sensitization and allergy were assessed in 526 house dust mite (HDM)-allergic patients submitted to the detection of IgE to Der p 10 and 100 atopic control not sensitized to HDM. Results. Shrimp allergy occurred in 9% of patients (vs 0% of 100 atopic controls not sensitized to HDM; p minor 0.001). Shrimp-allergic patients were less frequently hypersensitive to airborne allergens other than HDM than crustacean-tolerant subjects (35% vs 58.8%; p minor 0.005). Only 51% of tropomyosin-sensitized patients had shrimp allergy, and these showed significantly higher Der p 10 IgE levels than shrimp-tolerant ones (mean 22.2 KU/l vs 6.2 KU/l; p minor 0.05). Altogether 53% of shrimp-allergic patients did not react against tropomyosin. Conclusions. Shrimp allergy seems to occur uniquely in association with hypersensitivity to HDM allergens and tropomyosin is the main shrimp allergen but not a major one, at least in Italy. Along with tropomyosin-specific IgE levels, monosensitization to HDM seems to represent a risk factor for the development of shrimp allergy among HDM allergic patients.

Published
2019

20. Mast cells and acute coronary syndromes: Relationship between serum tryptase, clinical outcome and severity of coronary artery disease

Author

Morici, N, Farioli, L, Losappio, L, Colombo, G, Nichelatti, M, Preziosi, D, Micarelli, G, Oliva, F, Giannattasio, C, Klugmann, S, Pastorello, E, Pastorello, E., COLOMBO, GIULIA, GIANNATTASIO, CRISTINA, Morici, N, Farioli, L, Losappio, L, Colombo, G, Nichelatti, M, Preziosi, D, Micarelli, G, Oliva, F, Giannattasio, C, Klugmann, S, Pastorello, E, Pastorello, E., COLOMBO, GIULIA, and GIANNATTASIO, CRISTINA

Abstract

Objective: To assess the relationship between serum tryptase and the occurrence of major cardiovascular and cerebrovascular events (MACCE) at 2-year followup in patients admitted with acute coronary syndrome (ACS). To compare serum tryptase to other validated prognostic markers (maximum high-sensitivity troponin (hs-Tn), C reactive protein (CRP) levels at admission, Synergy between percutaneous coronary intervention with Taxus and Cardiac Surgery (SYNTAX) score). Methods: We measured serum tryptase at admission in 140 consecutive patients with ACS and in 50 healthy controls. The patients' follow-up was maintained for 2 years after discharge. The predictive accuracy of serum tryptase for 2-year MACCE was assessed and compared with hs-Tn, CRP and SYNTAX score. Results: Serum tryptase levels at admission were significantly higher in patients with ACS compared with the control group (p=0.0351). 2 years after discharge, 28/140 patients (20%) experienced MACCE. Serum tryptase levels, maximum hs-Tn measurements and SYNTAX score were higher in patients who experienced MACCE compared with those without (p<0.0001). Conversely, we found no significant association between MACCE and CRP. The predictive accuracy of serum tryptase for MACCE was set at the cut-off point of 6.7 ng/mL (sensitivity 46%, specificity 84%). Conclusions: In patients with ACS, serum tryptase measured during index admission is significantly correlated to the development of MACCE up to 2 years, demonstrating a possible long-term prognostic role of this biomarker.

Published
2016

24. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic overview of systematic reviews

Author

Nurmatov, U. Dhami, S. Arasi, S. Roberts, G. Pfaar, O. Muraro, A. Ansotegui, I.J. Calderon, M. Cingi, C. Durham, S. Van Wijk, R.G. Halken, S. Hamelmann, E. Hellings, P. Jacobsen, L. Knol, E. Larenas-Linnemann, D. Lin, S.Y. Maggina, V. Oude-Elberink, H. Pajno, G. Panwankar, R. Pastorello, E. Pitsios, C. Rotiroti, G. Timmermans, F. Tsilochristou, O. Varga, E.-M. Wilkinson, J. Williams, A. Worm, M. Zhang, L. Sheikh, A.

Abstract

Background: The European Academy of Allergy and Clinical Immunology (EAACI) is developing Guidelines on Allergen Immunotherapy (AIT) for Allergic Rhinoconjunctivitis (ARC). To inform the development of recommendations, we sought to critically assess the systematic review evidence on the effectiveness, safety and cost-effectiveness of AIT for ARC. Methods: We undertook a systematic overview, which involved searching nine international biomedical databases from inception to October 31, 2015. Studies were independently screened by two reviewers against pre-defined eligibility criteria and critically appraised using the Critical Appraisal Skills Programme (CASP) Systematic Review Checklist for systematic reviews. Data were descriptively synthesized. Results: Our searches yielded a total of 5932 potentially eligible studies, from which 17 systematic reviews met our inclusion criteria. Eight of these were judged to be of high, five moderate and three low quality. These reviews suggested that, in carefully selected patients, subcutaneous (SCIT) and sublingual (SLIT) immunotherapy resulted in significant reductions in symptom scores and medication requirements. Serious adverse outcomes were rare for both SCIT and SLIT. Two systematic reviews reported some evidence of potential cost savings associated with use of SCIT and SLIT. Conclusions: We found moderate-to-strong evidence that SCIT and SLIT can, in appropriately selected patients, reduce symptoms and medication requirements in patients with ARC with reassuring safety data. This evidence does however need to be interpreted with caution, particularly given the heterogeneity in the populations, allergens and protocols studied. There is a lack of data on the relative effectiveness, cost-effectiveness and safety of SCIT and SLIT. We are now systematically reviewing all the primary studies, including recent evidence that has not been incorporated into the published systematic reviews. © 2017 The Author(s).

Published
2017

25. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis

Author

Dhami, S. Nurmatov, U. Arasi, S. Khan, T. Asaria, M. Zaman, H. Agarwal, A. Netuveli, G. Roberts, G. Pfaar, O. Muraro, A. Ansotegui, I.J. Calderon, M. Cingi, C. Durham, S. van Wijk, R.G. Halken, S. Hamelmann, E. Hellings, P. Jacobsen, L. Knol, E. Larenas-Linnemann, D. Lin, S. Maggina, P. Mösges, R. Oude Elberink, H. Pajno, G. Panwankar, R. Pastorello, E. Penagos, M. Pitsios, C. Rotiroti, G. Timmermans, F. Tsilochristou, O. Varga, E.-M. Schmidt-Weber, C. Wilkinson, J. Williams, A. Worm, M. Zhang, L. Sheikh, A.

Abstract

Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing Guidelines on Allergen Immunotherapy (AIT) for Allergic Rhinoconjunctivitis. To inform the development of clinical recommendations, we undertook a systematic review to assess the effectiveness, cost-effectiveness, and safety of AIT in the management of allergic rhinoconjunctivitis. Methods: We searched nine international biomedical databases for published, in-progress, and unpublished evidence. Studies were independently screened by two reviewers against predefined eligibility criteria and critically appraised using established instruments. Our primary outcomes of interest were symptom, medication, and combined symptom and medication scores. Secondary outcomes of interest included cost-effectiveness and safety. Data were descriptively summarized and then quantitatively synthesized using random-effects meta-analyses. Results: We identified 5960 studies of which 160 studies satisfied our eligibility criteria. There was a substantial body of evidence demonstrating significant reductions in standardized mean differences (SMD) of symptom (SMD −0.53, 95% CI −0.63, −0.42), medication (SMD −0.37, 95% CI −0.49, −0.26), and combined symptom and medication (SMD −0.49, 95% CI −0.69, −0.30) scores while on treatment that were robust to prespecified sensitivity analyses. There was in comparison a more modest body of evidence on effectiveness post-discontinuation of AIT, suggesting a benefit in relation to symptom scores. Conclusions: AIT is effective in improving symptom, medication, and combined symptom and medication scores in patients with allergic rhinoconjunctivitis while on treatment, and there is some evidence suggesting that these benefits are maintained in relation to symptom scores after discontinuation of therapy. © 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Published
2017

26. Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy

Author

Novelli, Federica, Latorre, Matteo, Vergura, Letizia, Caiaffa, Maria Filomena, Camiciottoli, Gianna, Guarnieri, Gabriella, Matucci, Andrea, Macchia, Luigi, Vianello, Andrea, Vultaggio, Alessandra, Celi, Alessandro, Cazzola, Mario, Paggiaro, Pierluigi, Camiciottoli, G., Maselli, R., Pelaia, G., Busceti, M. T., Sabato, E., Cagnazzo, M. G., Colombo, F., Palumbo, Laura, Ravazzi, Aldo, Bucca, C., Caiaffa, M. F., Berra, A., Calabrese, C., Stanziola, A. A., Schino, P., Di Gioacchino, M., Cazzola, M., Segreti, A., Pastorello, E. A., Scibilia, G., Vianello, A., Marchi, M. R., Paladini, L., Baglioni, S., Abbritti, M., Almerigogna, F., Matucci, A., Vultaggio, A., Maggi, E., Maestrelli, P., Guarnieri, G., Steinhilber, G., Bonavia, M., Rottoli, P., Bargagli, E., Senna, G., Caminati, M., Macchia, L., Bellia, V., Scichilone, N., Paggiaro, P., Novelli, F., Vergura, L., Novelli F., Latorre M., Vergura L., Caiaffa M.F., Camiciottoli G., Guarnieri G., Matucci A., Macchia L., Vianello A., Vultaggio A., Celi A., Cazzola M., Paggiaro P., Maselli R., Pelaia G., Busceti M.T., Sabato E., Cagnazzo M.G., Colombo F., Palumbo L., Ravazzi A., Bucca C., Berra A., Calabrese C., Stanziola A.A., Schino P., Di Gioacchino M., Segreti A., Pastorello E.A., Scibilia G., Marchi M.R., Paladini L., Baglioni S., Abbritti M., Almerigogna F., Maggi E., Maestrelli P., Steinhilber G., Bonavia M., Rottoli P., Bargagli E., Senna G., Caminati M., Bellia V., Scichilone N., Novelli, F., Latorre, M., Vergura, L., Caiaffa, M. F., Camiciottoli, G., Guarnieri, G., Matucci, A., Macchia, L., Vianello, A., Vultaggio, A., Celi, A., Cazzola, M., Paggiaro, P., Maselli, R., Pelaia, G., Busceti, M. T., Sabato, E., Cagnazzo, M. G., Colombo, F., Palumbo, L., Ravazzi, A., Bucca, C., Berra, A., Calabrese, C., Stanziola, A. A., Schino, P., Di Gioacchino, M., Segreti, A., Pastorello, E. A., Scibilia, G., Marchi, M. R., Paladini, L., Baglioni, S., Abbritti, M., Almerigogna, F., Maggi, E., Maestrelli, P., Steinhilber, G., Bonavia, M., Rottoli, P., Bargagli, E., Senna, G., Caminati, M., Bellia, V., and Scichilone, N.

Subjects
Adult, Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Exacerbation, Cross-sectional study, Omalizumab, Comorbidity, Settore MED/10 - Malattie Dell'Apparato Respiratorio, Exhaled nitric oxide, Exacerbations, Comorbidities, Asthma, Control, Severity of Illness Index, Internal medicine, Severity of illness, Medicine, Anti-Asthmatic Agent, Humans, Pharmacology (medical), Anti-Asthmatic Agents, Inflammation Mediator, Respiratory Function Test, Aged, Cross-Sectional Studie, business.industry, Biochemistry (medical), Middle Aged, medicine.disease, Respiratory Function Tests, Cross-Sectional Studies, Italy, Physical therapy, Observational study, Female, Inflammation Mediators, Comorbiditie, business, medicine.drug, Human
Abstract

Few data are available on the proportion of asthmatics achieving a good asthma control (according GINA guidelines) and on the level of airway inflammation during omalizumab treatment. The aim of this cross-sectional national observational study was to assess the level of control (according to GINA guidelines) achieved in a group of asthmatics on omalizumab treatment, and to characterize the factors that influence the lack of control. We studied 306 asthmatics under omalizumab treatment for a median of 32 months (range 4-120). The level of control according to GINA was good in 25.2%, partial in 47.1% and poor in 24.5% of patients (data were missing for the remaining 3.2%). Comparison between poorly controlled and partially or well controlled asthmatics showed a statistically significant higher prevalence of some comorbidities in the first group, namely obesity, gastro-oesophageal reflux disease (GORD), aspirin intolerance and mental disorders (all p

Published
2015

27. Allergen immunotherapy for allergic rhinoconjunctivitis : A systematic review and meta-analysis

Author

Dhami, S., Nurmatov, U., Arasi, S., Khan, T., Asaria, M., Zaman, H., Agarwal, A., Netuveli, G., Roberts, G., Pfaar, O., Muraro, A., Ansotegui, I. J., Calderon, M., Cingi, C., Durham, S., van Wijk, R. Gerth, Halken, S., Hamelmann, E., Hellings, P., Jacobsen, L., Knol, E., Larenas-Linnemann, D., Lin, S., Maggina, P., Mösges, R., Oude Elberink, H., Pajno, G., Panwankar, R., Pastorello, E., Penagos, M., Pitsios, C., Rotiroti, G., Timmermans, F., Tsilochristou, O., Varga, E. M., Schmidt-Weber, C., Wilkinson, J., Williams, A., Worm, M., Zhang, L., Sheikh, A., Dhami, S., Nurmatov, U., Arasi, S., Khan, T., Asaria, M., Zaman, H., Agarwal, A., Netuveli, G., Roberts, G., Pfaar, O., Muraro, A., Ansotegui, I. J., Calderon, M., Cingi, C., Durham, S., van Wijk, R. Gerth, Halken, S., Hamelmann, E., Hellings, P., Jacobsen, L., Knol, E., Larenas-Linnemann, D., Lin, S., Maggina, P., Mösges, R., Oude Elberink, H., Pajno, G., Panwankar, R., Pastorello, E., Penagos, M., Pitsios, C., Rotiroti, G., Timmermans, F., Tsilochristou, O., Varga, E. M., Schmidt-Weber, C., Wilkinson, J., Williams, A., Worm, M., Zhang, L., and Sheikh, A.

Published
2017

28. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic overview of systematic reviews

Author

Nurmatov, U. (Ulugbek), Dhami, S. (Sangeeta), Arasi, S. (Stefania), Roberts, G., Pfaar, O. (Oliver), Muraro, A. (Antonella), Ansotegui, I.J. (I.), Calderon, M. (Moises), Cingi, C. (Cemal), Durham, S. (Stephen), Gerth van Wijk, R. (Roy), Halken, S. (Susanne), Hamelmann, E. (Eckard), Hellings, P.W. (Peter), Jacobsen, L., Knol, E.F. (Edward Frank), Larenas-Linnemann, D. (Désirée), Lin, S.Y. (Sandra Y.), Maggina, V. (Vivian), Oude Elberink, H.N.G. (Hanneke N.G.), Pajno, G. (G.), Panwankar, R. (Ruby), Pastorello, E. (Elideanna), Pitsios, C., Rotiroti, G. (Giuseppina), Timmermans, F. (Frans), Tsilochristou, O. (Olympia), Varga, E.M., Wilkinson, J. (Jamie), Williams, A. (Andrew), Worm, M. (M.), Zhang, L. (Luo), Sheikh, A. (Aziz), Nurmatov, U. (Ulugbek), Dhami, S. (Sangeeta), Arasi, S. (Stefania), Roberts, G., Pfaar, O. (Oliver), Muraro, A. (Antonella), Ansotegui, I.J. (I.), Calderon, M. (Moises), Cingi, C. (Cemal), Durham, S. (Stephen), Gerth van Wijk, R. (Roy), Halken, S. (Susanne), Hamelmann, E. (Eckard), Hellings, P.W. (Peter), Jacobsen, L., Knol, E.F. (Edward Frank), Larenas-Linnemann, D. (Désirée), Lin, S.Y. (Sandra Y.), Maggina, V. (Vivian), Oude Elberink, H.N.G. (Hanneke N.G.), Pajno, G. (G.), Panwankar, R. (Ruby), Pastorello, E. (Elideanna), Pitsios, C., Rotiroti, G. (Giuseppina), Timmermans, F. (Frans), Tsilochristou, O. (Olympia), Varga, E.M., Wilkinson, J. (Jamie), Williams, A. (Andrew), Worm, M. (M.), Zhang, L. (Luo), and Sheikh, A. (Aziz)

Published
2017
Full Text
View/download PDF

29. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis

Author

CTI, MS Dermatologie/Allergologie, Infection & Immunity, CDL Celdiagnostiek, Dhami, S., Nurmatov, U., Arasi, S., Khan, T., Asaria, M., Zaman, H., Agarwal, A., Netuveli, G., Roberts, G., Pfaar, O., Muraro, A., Ansotegui, I. J., Calderon, M., Cingi, C., Durham, S., van Wijk, R. Gerth, Halken, S., Hamelmann, E., Hellings, P., Jacobsen, L., Knol, E., Larenas-Linnemann, D., Lin, S., Maggina, P., Mösges, R., Oude Elberink, H., Pajno, G., Panwankar, R., Pastorello, E., Penagos, M., Pitsios, C., Rotiroti, G., Timmermans, F., Tsilochristou, O., Varga, E. M., Schmidt-Weber, C., Wilkinson, J., Williams, A., Worm, M., Zhang, L., Sheikh, A., CTI, MS Dermatologie/Allergologie, Infection & Immunity, CDL Celdiagnostiek, Dhami, S., Nurmatov, U., Arasi, S., Khan, T., Asaria, M., Zaman, H., Agarwal, A., Netuveli, G., Roberts, G., Pfaar, O., Muraro, A., Ansotegui, I. J., Calderon, M., Cingi, C., Durham, S., van Wijk, R. Gerth, Halken, S., Hamelmann, E., Hellings, P., Jacobsen, L., Knol, E., Larenas-Linnemann, D., Lin, S., Maggina, P., Mösges, R., Oude Elberink, H., Pajno, G., Panwankar, R., Pastorello, E., Penagos, M., Pitsios, C., Rotiroti, G., Timmermans, F., Tsilochristou, O., Varga, E. M., Schmidt-Weber, C., Wilkinson, J., Williams, A., Worm, M., Zhang, L., and Sheikh, A.

Published
2017

30. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews

Author

Nurmatov, U, Dhami, S, Arasi, S, Roberts, G, Pfaar, O, Muraro, A, Ansotegui, IJ, Calderon, M, Cingi, C, Durham, S, Gerth van Wijk, Roy, Halken, S, Hamelmann, E, Hellings, P, Jacobsen, L, Knol, E, Larenas-Linnemann, D, Lin, SY, Maggina, V, Oude-Elberink, H, Pajno, G, Panwankar, R, Pastorello, E, Pitsios, C, Rotiroti, G, Timmermans, F, Tsilochristou, O, Varga, EM, Wilkinson, J, Williams, A, van den Worm, M (M.), Zhang, Lei, Sheikh, A (Aziz), Nurmatov, U, Dhami, S, Arasi, S, Roberts, G, Pfaar, O, Muraro, A, Ansotegui, IJ, Calderon, M, Cingi, C, Durham, S, Gerth van Wijk, Roy, Halken, S, Hamelmann, E, Hellings, P, Jacobsen, L, Knol, E, Larenas-Linnemann, D, Lin, SY, Maggina, V, Oude-Elberink, H, Pajno, G, Panwankar, R, Pastorello, E, Pitsios, C, Rotiroti, G, Timmermans, F, Tsilochristou, O, Varga, EM, Wilkinson, J, Williams, A, van den Worm, M (M.), Zhang, Lei, and Sheikh, A (Aziz)

Published
2017

31. Allergy immunotherapy across the life cycle to promote active and healthy ageing : from research to policies

Author

Calderon, M. A., Demoly, P., Casale, T., Akdis, C. A., Bachert, C., Bewick, M., Bilo, B. M., Bohle, B., Bonini, S., Bush, A., Caimmi, D. P., Canonica, G. W., Cardona, V., Chiriac, A. M., Cox, L., Custovic, A., De Blay, F., Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G., Durham, S. R., Eng, P., Fiocchi, A., Fox, A. T., van Wijk, R. Gerth, Gomez, R. M., Haahtela, Tari Markku Kallevi, Halken, S., Hellings, P. W., Jacobsen, L., Just, J., Tanno, L. K., Kleine-Tebbe, J., Klimek, L., Knol, E. F., Kuna, P., Larenas-Linnemann, D. E., Linneberg, A., Matricardi, M., Malling, H. J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G., Pastorello, E., Pfaar, O., Price, D., Rodriguez del Rio, P., Rueff, R., Samolinski, B., Scadding, G. K., Senti, G., Shamji, M. H., Sheikh, A., Sisul, J. C., Sole, D., Sturm, G. J., Tabar, A., Van Ree, R., Ventura, M. T., Vidal, C., Varga, E. M., Worm, M., Zuberbier, T., Bousquet, J., Clinicum, and Department of Dermatology, Allergology and Venereology

Subjects
EIP on AHA, EAACI POSITION PAPER, RUSH IMMUNOTHERAPY, GRASS-POLLEN ALLERGY, INTERNATIONAL CONSENSUS, EUROPEAN INNOVATION PARTNERSHIP, NATIONAL DATABASES, ORAL IMMUNOTHERAPY, Asthma, Ageing, AIRWAYS ICPs, SUBLINGUAL IMMUNOTHERAPY, PRECISION MEDICINE, IMMUNOLOGY/PRACTALL CONSENSUS REPORT, 3121 General medicine, internal medicine and other clinical medicine, Allergen immunotherapy, Rhinitis
Abstract

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

Published
2016

32. Allergy immunotherapy across the life cycle to promote active and healthy ageing : from research to policies

Author

Calderon, MA, Demoly, P, Casale, T, Akdis, CA, Bachert, C, Bewick, M, Bilo, BM, Bohle, B, Bonini, S, Bush, A, Caimmi, DP, Canonica, GW, Cardona, V, Chiriac, AM, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, SR, Eng, P, Fiocchi, A, Fox, AT, Van Wijk, RG, Gomez, RM, Haathela, T, Halken, S, Hellings, PW, Jacobsen, L, Just, J, Tanno, LK, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, DE, Linneberg, A, Matricardi, M, Malling, HJ, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Rodriguez del Rio, P, Rueff, R, Samolinski, B, Scadding, GK, Senti, G, Shamji, MH, Sheikh, A, Sisul, JC, Sole, D, Sturm, GJ, Tabar, A, Van Ree, R, Ventura, MT, Vidal, C, Varga, EM, Worm, M, Zuberbier, T, Bousquet, J, Internal Medicine, and Medical Research Council (MRC)

Subjects
Pulmonary and Respiratory Medicine, EIP on AHA, Science & Technology, EAACI POSITION PAPER, RUSH IMMUNOTHERAPY, Allergy, GRASS-POLLEN ALLERGY, INTERNATIONAL CONSENSUS, EUROPEAN INNOVATION PARTNERSHIP, Immunology, NATIONAL DATABASES, ORAL IMMUNOTHERAPY, Ageing, AIRWAYS ICPs, Allergen immunotherapy, Asthma, Rhinitis, Immunology and Allergy, SUBLINGUAL IMMUNOTHERAPY, PRECISION MEDICINE, IMMUNOLOGY/PRACTALL CONSENSUS REPORT, Medicine and Health Sciences, Life Sciences & Biomedicine
Abstract

European Innovation Partnership on Active and Healthy Ageing Reference Site MACVIA-France, European Structural and Development Funds of Region Languedoc Roussillon Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing. Imperial Coll London, Natl Heart & Lung Inst, Royal Brompton Hosp NHS, London, England UPMC Paris 06, Sorbonne Univ,Dept Pneumol & Addictol,UMR S 1136, Hop Arnaud de Villeneuve,CHRU Montpellier, IPLESP,Equipe EPAR,Unite Allergol, F-75013 Paris, France Univ S Florida, Morsani Coll Med, Tampa, FL USA Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Christine Kuhne Ctr Allergy Res & Educ CK CARE, Davos, Switzerland Univ Hosp Ghent, ENT Dept, Upper Airways Res Lab URL, Ghent, Belgium IQ4U Consultants Ltd, London, England Osped Riuniti, Univ Hosp, Allergy Unit, Dept Internal Med, Ancona, Italy Med Univ Vienna, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria Univ Naples 2, Rome, Italy CNR, IFT, Rome, Italy Univ Genoa, Allergy & Resp Dis Clin, DIMI, IRCCS AOU San Martino IST, Genoa, Italy Hosp Univ Vall dHebron, Allergy Sect, Dept Internal Med, Barcelona, Spain Montpellier UPMC Univ Paris 06, Sorbonne Univ,UMRS 1136, Hop Arnaud de Villeneuve,Equipe EPAR IPLESP, Div Allergy,Dept Pulmonol,Univ Hosp Montpellier, Paris, France Nova Southeastern Univ, Ft Lauderdale, FL USA Univ Hosp Strasbourg, Div Allergy, Chest Dis Dept, Strasbourg, France Univ Versailles St Quentin, Suresnes, France Foch Hosp, Dept Airway Dis, Clin Pharmacol Unit, UPRES EA 220, Suresnes, France Rangueil Larrey Hosp, Dept Resp Dis, Toulouse, France Univ Palermo, Di Bi MIS, Palermo, Italy Kings Coll London, Guys & St Thomas NHS Trust, London, England Imperial Coll London, Natl Heart & Lung Inst, Allergy & Clin Immunol Sect, London, England Childrens Hosp, Dept Pediat Pulmonol & Allergy, Aarau, Switzerland Bambino Gesu Pediat Hosp, Dept Pediat, Div Allergy, Rome, Italy Kings Coll London, Allergy Acad, London, England Erasmus MC, Dept Internal Med, Bldg Rochussenstr, Rotterdam, Netherlands Hosp San Bernardo, Unidad Alergia & Asma, Salta, Argentina Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland Odense Univ Hosp, Hans Christian Andersen Childrens Hosp, Odense, Denmark Katholieke Univ Leuven, Univ Hosp Leuven, Clin Dept Otorhinolaryngol Head & Neck Surg, Louvain, Belgium Secretary Immunotherapy Interest Grp EAACI, Allergy Learning & Consulting, Copenhagen, Denmark UPMC Univ Paris, Sorbonne Univ,Hop Enfants Armand Trousseau,INSERM, Inst Pierre Louis Epidemiol & Sante Publ,Equipe E, Allergol Dept,Ctr Asthme & Allergies,UMR S 1136, Paris, France Hosp Sirio Libanes, Sao Paulo, Brazil Univ Hosp Montpellier, Montpellier, France UPMC Paris 06, Sorbonne Univ, Equipe EPAR, UMR S 1136,IPLESP, Paris, France Ackermann Hanf & Kleine Tebbe, Outpatient Clin & Clin Res Ctr, Allergy & Asthma Ctr Westend, Berlin, Germany German Soc Otorhinolaryngol HNS, Ctr Rhinol & Allergol, Wiesbaden, Germany Univ Med Ctr Utrecht, Dept Immunol & Dermatol Allergol, Utrecht, Netherlands Med Univ Lodz, Lodz, Poland ARIA, Mexico City, DF, Mexico Hosp Med Sur, AAAAI, Mexico City, DF, Mexico Capital Reg Denmark, Res Ctr Prevent & Hlth, Copenhagen, Denmark Rigshosp, Dept Clin Expt Res, Copenhagen, Denmark Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark Charite Med Univ, Pediat Pneumol & Immunol, Berlin, Germany Gentofte Univ Hosp, Allergy Clin, Danish Allergy Ctr, Hellerup, Denmark Klinikum Univ Koln AoR, IMSIE, Cologne, Germany Hosp Clin Barcelona, Unitat Rinol & Clin Olfacte, ENT Dept, Clin & Expt Resp Immunoallergy,IDIBAPS,CIBERES, Barcelona, Catalonia, Spain Padua Gen Univ Hosp, Dept Women & Child Hlth, Food Allergy Referral Ctr Veneto Reg, Padua, Italy Univ Athens, Allergy Unit, Pediat Clin 2, Athens, Greece Univ Genoa, Allergy & Resp Dis, IRCCS San Martino IST, Genoa, Italy ASST Grande Osped Metropolitano Niguarda, Pzza Osped Maggiore, Milan, Italy Univ Med Mannheim, Dept Otorhinolaryngol Head & Neck Surg, Mannheim, Germany Heidelberg Univ, Med Fac Mannheim, Heidelberg, Germany Ctr Rhinol & Allergol, Wiesbaden, Germany Univ Aberdeen, Acad Primary Care, Div Appl Hlth Sci, Primary Care Resp Med, Aberdeen, Scotland RiRL, Cambridge, England Optimum Patient Care Ltd, Singapore, Singapore Hosp Infantil Univ Nino Jesus, Allergy Sect, Madrid, Spain Ludwig Maximillian Univ, Dept Dermatol & Allergol, Munich, Germany Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, Warsaw, Poland Royal Natl Throat Nose & Ear Hosp, London, England UCL, London, England Univ Zurich Hosp, Clin Trials Ctr, Zurich, Switzerland Imperial Coll London, Natl Heart & Lung Inst, Allergy & Clin Immunol Inflammat Repair & Dev Sec, Immunomodulat & Tolerance Grp,Fac Med, London, England MRC, London, England Asthma UK Ctr Allerg Mechanisms Asthma, London, England Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Asthma UK Ctr Appl Res, Med Informat Ctr, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland SLAAI, Asuncion, Paraguay Univ Fed Sao Paulo, Programa Posgrad Pediat & Ciencias Aplicadas Pedi, Dept Pediat EPM, Sao Paulo, Brazil Med Univ Graz, Dept Dermatol & Venerol, Graz, Austria Allergy Outpatient Clin Reumannplatz, Vienna, Austria Complejo Hosp Navarra, Serv Alergol, Pamplona, Spain Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, Amsterdam, Netherlands Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands Univ Bari, Sch Med, Unit Geriatr Immunoallergol, Interdisciplinary Dept Med, Bari, Italy Complejo Hosp Univ Santiago de Compostela, Dept Allergy, Santiago De Compostela, Spain Med Univ Graz, Dept Paediat, Resp & Allerg Dis Div, Graz, Austria Charite Univ Med Berlin, Klin Dermatol Venerol & Allergol, Allergie Ctr Charite, Berlin, Germany European Innovat Partnership Act & Hlth Ageing Re, MAlad Chron Vleillissement Actif Languedoc Roussi, Paris, France INSERM, VIMA, Epidemiol & Publ Hlth Approaches, U1168,Ageing & Chron Dis, Paris, France Univ Versailles St Quentin En Yvelines, UVSQ, UMR S 1168, Versailles, France CHRU, 371 Ave Doyen Gaston Giraud, F-34295 Montpellier 5, France Programa de Pòs‑Graduação em Pediatria e Ciências Aplicadas à Pediatria, Departamento de Pediatria EPM, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil Web of Science

Published
2016

33. Allergy immunotherapy across the life cycle to promote active and healthy ageing: From research to policies

Author

Calderon, M.A. Demoly, P. Casale, T. Akdis, C.A. Bachert, C. Bewick, M. Bilò, B.M. Bohle, B. Bonini, S. Bush, A. Caimmi, D.P. Canonica, G.W. Cardona, V. Chiriac, A.M. Cox, L. Custovic, A. De Blay, F. Devillier, P. Didier, A. Di Lorenzo, G. Du Toit, G. Durham, S.R. Eng, P. Fiocchi, A. Fox, A.T. Van Wijk, R.G. Gomez, R.M. Haathela, T. Halken, S. Hellings, P.W. Jacobsen, L. Just, J. Tanno, L.K. Kleine-Tebbe, J. Klimek, L. Knol, E.F. Kuna, P. Larenas-Linnemann, D.E. Linneberg, A. Matricardi, M. Malling, H.J. Moesges, R. Mullol, J. Muraro, A. Papadopoulos, N. Passalacqua, G. Pastorello, E. Pfaar, O. Price, D. Del Rio, P.R. Ruëff, R. Samolinski, B. Scadding, G.K. Senti, G. Shamji, M.H. Sheikh, A. Sisul, J.C. Sole, D. Sturm, G.J. Tabar, A. Van Ree, R. Ventura, M.T. Vidal, C. Varga, E.M. Worm, M. Zuberbier, T. Bousquet, J.

Abstract

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing. © 2016 The Author(s).

Published
2016

34. EAACI Molecular Allergology User's Guide

Author

Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., Ollert, M., Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., and Ollert, M.

Published
2016

35. Allergy immunotherapy across the life cycle to promote active and healthy ageing : from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project

Author

Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, Bousquet, J, Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, and Bousquet, J

Published
2016

36. Allergy immunotherapy across the life cycle to promote active and healthy ageing

Author

University of Helsinki, Clinicum, Calderon, M. A., Demoly, P., Casale, T., Akdis, C. A., Bachert, C., Bewick, M., Bilo, B. M., Bohle, B., Bonini, S., Bush, A., Caimmi, D. P., Canonica, G. W., Cardona, V., Chiriac, A. M., Cox, L., Custovic, A., De Blay, F., Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G., Durham, S. R., Eng, P., Fiocchi, A., Fox, A. T., van Wijk, R. Gerth, Gomez, R. M., Haahtela, Tari Markku Kallevi, Halken, S., Hellings, P. W., Jacobsen, L., Just, J., Tanno, L. K., Kleine-Tebbe, J., Klimek, L., Knol, E. F., Kuna, P., Larenas-Linnemann, D. E., Linneberg, A., Matricardi, M., Malling, H. J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G., Pastorello, E., Pfaar, O., Price, D., Rodriguez del Rio, P., Rueff, R., Samolinski, B., Scadding, G. K., Senti, G., Shamji, M. H., Sheikh, A., Sisul, J. C., Sole, D., Sturm, G. J., Tabar, A., Van Ree, R., Ventura, M. T., Vidal, C., Varga, E. M., Worm, M., Zuberbier, T., Bousquet, J., University of Helsinki, Clinicum, Calderon, M. A., Demoly, P., Casale, T., Akdis, C. A., Bachert, C., Bewick, M., Bilo, B. M., Bohle, B., Bonini, S., Bush, A., Caimmi, D. P., Canonica, G. W., Cardona, V., Chiriac, A. M., Cox, L., Custovic, A., De Blay, F., Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G., Durham, S. R., Eng, P., Fiocchi, A., Fox, A. T., van Wijk, R. Gerth, Gomez, R. M., Haahtela, Tari Markku Kallevi, Halken, S., Hellings, P. W., Jacobsen, L., Just, J., Tanno, L. K., Kleine-Tebbe, J., Klimek, L., Knol, E. F., Kuna, P., Larenas-Linnemann, D. E., Linneberg, A., Matricardi, M., Malling, H. J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G., Pastorello, E., Pfaar, O., Price, D., Rodriguez del Rio, P., Rueff, R., Samolinski, B., Scadding, G. K., Senti, G., Shamji, M. H., Sheikh, A., Sisul, J. C., Sole, D., Sturm, G. J., Tabar, A., Van Ree, R., Ventura, M. T., Vidal, C., Varga, E. M., Worm, M., Zuberbier, T., and Bousquet, J.

Abstract

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

Published
2016

37. Allergy immunotherapy across the life cycle to promote active and healthy ageing: From research to policies

Author

Calderon, M. (Moises), Demoly, P., Casale, T.B. (Thomas), Akdis, C.A., Bachert, C. (Claus), Bewick, M., Bilò, B.M., Bohle, B. (B.), Bonini, S. (Sergio), Bush, A. (Andrew), Caimmi, D.P., Canonica, G. (Gwalter), Cardona, D. (Doris), Chiriac, A.M. (A.), Cox, L. (Linda), Custovic, A. (Adnan), Blay, F. de, Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G. (George), Durham, S.R. (Stephen), Eng, C. (Charis), Fiocchi, A. (Alessandro), Fox, A.T., Gerth van Wijk, R. (Roy), Gomez, R.M., Haathela, T., Halken, S. (Susanne), Hellings, P.W. (Peter), Jacobsen, L., Just, P.M., Tanno, L.K., Kleine-Tebbe, J. (Jörg), Klimek, L. (Ludger), Knol, E.F. (Edward Frank), Kuna, P. (Piotr), Larenas-Linnemann, D. (Désirée), Linneberg, A. (Allan), Matricardi, M., Malling, H.-J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G. (Giovanni), Pastorello, E., Pfaar, O. (Oliver), Price, D. (David), Del Rio, P.R. (P. Rodriguez), Ruëff, R., Samolinski, B., Scadding, G.K., Senti, G., Shamji, M.H., Sheikh, A. (Aziz), Sisul, J.C. (J.), Solé, D. (D.), Sturm, G.J., Tabar, A., Van Ree, R., Ventura, M.T., Vidal, C. (Carmen), Varga, E.M., Worm, M. (M.), Zuberbier, T. (Torsten), Bousquet, J. (Jean), Calderon, M. (Moises), Demoly, P., Casale, T.B. (Thomas), Akdis, C.A., Bachert, C. (Claus), Bewick, M., Bilò, B.M., Bohle, B. (B.), Bonini, S. (Sergio), Bush, A. (Andrew), Caimmi, D.P., Canonica, G. (Gwalter), Cardona, D. (Doris), Chiriac, A.M. (A.), Cox, L. (Linda), Custovic, A. (Adnan), Blay, F. de, Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G. (George), Durham, S.R. (Stephen), Eng, C. (Charis), Fiocchi, A. (Alessandro), Fox, A.T., Gerth van Wijk, R. (Roy), Gomez, R.M., Haathela, T., Halken, S. (Susanne), Hellings, P.W. (Peter), Jacobsen, L., Just, P.M., Tanno, L.K., Kleine-Tebbe, J. (Jörg), Klimek, L. (Ludger), Knol, E.F. (Edward Frank), Kuna, P. (Piotr), Larenas-Linnemann, D. (Désirée), Linneberg, A. (Allan), Matricardi, M., Malling, H.-J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G. (Giovanni), Pastorello, E., Pfaar, O. (Oliver), Price, D. (David), Del Rio, P.R. (P. Rodriguez), Ruëff, R., Samolinski, B., Scadding, G.K., Senti, G., Shamji, M.H., Sheikh, A. (Aziz), Sisul, J.C. (J.), Solé, D. (D.), Sturm, G.J., Tabar, A., Van Ree, R., Ventura, M.T., Vidal, C. (Carmen), Varga, E.M., Worm, M. (M.), Zuberbier, T. (Torsten), and Bousquet, J. (Jean)

Abstract

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

Published
2016
Full Text
View/download PDF

38. Allergen immunotherapy for allergic rhinoconjunctivitis: Protocol for a systematic review

Author

Dhami, S. (Sangeeta), Nurmatov, U. (Ulugbek), Roberts, G., Pfaar, O. (Oliver), Muraro, A. (Antonella), Ansotegui, I.J. (I.), Calderon, M. (Moises), Cingi, C. (Cemal), Demoly, P., Durham, S.R. (Stephen), Gerth van Wijk, R. (Roy), Halken, S. (Susanne), Hamelmann, E. (Eckard), Hellings, P.W. (Peter), Jacobsen, L., Knol, E.F. (Edward Frank), Linnemann, D.L. (D. Larenas), Lin, S. (Sandra), Maggina, V. (Vivian), Oude Elberink, H.N.G. (Hanneke N.G.), Pajno, G. (G.), Panwankar, R. (Ruby), Pastorello, E. (Elideanna), Pitsios, C., Rotiroti, G. (Giuseppina), Timmermans, F. (Frans), Tsilochristou, O. (Olympia), Varga, E.M., Wilkinson, J. (Jamie), Williams, A. (Andrew), Worm, M. (M.), Zhang, L. (Luo), Sheikh, A. (Aziz), Dhami, S. (Sangeeta), Nurmatov, U. (Ulugbek), Roberts, G., Pfaar, O. (Oliver), Muraro, A. (Antonella), Ansotegui, I.J. (I.), Calderon, M. (Moises), Cingi, C. (Cemal), Demoly, P., Durham, S.R. (Stephen), Gerth van Wijk, R. (Roy), Halken, S. (Susanne), Hamelmann, E. (Eckard), Hellings, P.W. (Peter), Jacobsen, L., Knol, E.F. (Edward Frank), Linnemann, D.L. (D. Larenas), Lin, S. (Sandra), Maggina, V. (Vivian), Oude Elberink, H.N.G. (Hanneke N.G.), Pajno, G. (G.), Panwankar, R. (Ruby), Pastorello, E. (Elideanna), Pitsios, C., Rotiroti, G. (Giuseppina), Timmermans, F. (Frans), Tsilochristou, O. (Olympia), Varga, E.M., Wilkinson, J. (Jamie), Williams, A. (Andrew), Worm, M. (M.), Zhang, L. (Luo), and Sheikh, A. (Aziz)

Abstract

Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines for Allergen Immunotherapy (AIT) for the Management of Allergic Rhinoconjunctivitis. We seek to critically assess the effectiveness, cost-effectiveness and safety of AIT in the management of allergic rhinoconjunctivitis. Methods: We will undertake a systematic review, which will involve searching international biomedical databases for published, in progress and unpublished evidence. Studies will be independently scree

Published
2016
Full Text
View/download PDF

39. Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project

Author

MS Dermatologie/Allergologie, CDL Celdiagnostiek, Infection & Immunity, Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, Bousquet, J, MS Dermatologie/Allergologie, CDL Celdiagnostiek, Infection & Immunity, Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, and Bousquet, J

Published
2016

40. EAACI Molecular Allergology User's Guide

Author

MS Dermatologie/Allergologie, CDL Celdiagnostiek, Infection & Immunity, Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., Ollert, M., MS Dermatologie/Allergologie, CDL Celdiagnostiek, Infection & Immunity, Matricardi, P. M., Kleine-Tebbe, J., Hoffmann, H. J., Valenta, R., Hilger, C., Hofmaier, S., Aalberse, R. C., Agache, I., Asero, R., Ballmer-Weber, B., Barber, D., Beyer, K., Biedermann, T., Bilò, M. B., Blank, S., Bohle, B., Bosshard, P. P., Breiteneder, H., Brough, H. A., Caraballo, L., Caubet, J. C., Crameri, R., Davies, J. M., Douladiris, N., Ebisawa, M., EIgenmann, P. A., Fernandez-Rivas, M., Ferreira, F., Gadermaier, G., Glatz, M., Hamilton, R. G., Hawranek, T., Hellings, P., Hoffmann-Sommergruber, K., Jakob, T., Jappe, U., Jutel, M., Kamath, S. D., Knol, E. F., Korosec, P., Kuehn, A., Lack, G., Lopata, A. L., Mäkelä, M., Morisset, M., Niederberger, V., Nowak-Węgrzyn, A. H., Papadopoulos, N. G., Pastorello, E. A., Pauli, G., Platts-Mills, T., Posa, D., Poulsen, L. K., Raulf, M., Sastre, J., Scala, E., Schmid, J. M., Schmid-Grendelmeier, P., van Hage, M., van Ree, R., Vieths, S., Weber, R., Wickman, M., Muraro, A., and Ollert, M.

Published
2016

41. Allergy immunotherapy across the life cycle to promote active and healthy ageing:from research to policies: An AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases (GARD), a World Health Organization GARD research demonstration project

Author

Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, E F, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, Bousquet, J, Calderon, M A, Demoly, P, Casale, T, Akdis, C A, Bachert, C, Bewick, M, Bilò, B M, Bohle, B, Bonini, S, Bush, A, Caimmi, D P, Canonica, G W, Cardona, V, Chiriac, A M, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, S R, Eng, P, Fiocchi, A, Fox, A T, van Wijk, R Gerth, Gomez, R M, Haathela, T, Halken, S, Hellings, P W, Jacobsen, L, Just, J, Tanno, L K, Kleine-Tebbe, J, Klimek, L, Knol, E F, Kuna, P, Larenas-Linnemann, D E, Linneberg, A, Matricardi, M, Malling, H J, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Del Rio, P Rodriguez, Ruëff, R, Samolinski, B, Scadding, G K, Senti, G, Shamji, M H, Sheikh, A, Sisul, J C, Sole, D, Sturm, G J, Tabar, A, Van Ree, R, Ventura, M T, Vidal, C, Varga, E M, Worm, M, Zuberbier, T, and Bousquet, J

Abstract

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

Published
2016

42. EAACI molecular allergology user's guide

Author

Matricardi, P M, Kleine-Tebbe, J, Hoffmann, H.J., Valenta, R, Hilger, C, Hofmaier, S, Aalberse, R C, Agache, I, Asero, R, Ballmer-Weber, B, Barber, D, Beyer, K, Biedermann, T, Bilò, M B, Blank, S, Bohle, B, Bosshard, P P, Breiteneder, H, Brough, H A, Caraballo, L, Caubet, J C, Crameri, R, Davies, J M, Douladiris, N, Ebisawa, M, EIgenmann, P A, Fernandez-Rivas, M, Ferreira, F, Gadermaier, G, Glatz, M, Hamilton, R G, Hawranek, T, Hellings, P, Hoffmann-Sommergruber, K, Jakob, T, Jappe, U, Jutel, M, Kamath, S D, Knol, E F, Korosec, P, Kuehn, A, Lack, G, Lopata, A L, Mäkelä, M, Morisset, M, Niederberger, V, Nowak-Węgrzyn, A H, Papadopoulos, N G, Pastorello, E A, Pauli, G, Platts-Mills, T, Posa, D, Poulsen, L. K., Raulf, M, Sastre, J, Scala, E, Schmid, J M, Schmid-Grendelmeier, P, van Hage, M, van Ree, R, Vieths, S, Weber, R, Wickman, M, Muraro, A, Ollert, M., Matricardi, P M, Kleine-Tebbe, J, Hoffmann, H.J., Valenta, R, Hilger, C, Hofmaier, S, Aalberse, R C, Agache, I, Asero, R, Ballmer-Weber, B, Barber, D, Beyer, K, Biedermann, T, Bilò, M B, Blank, S, Bohle, B, Bosshard, P P, Breiteneder, H, Brough, H A, Caraballo, L, Caubet, J C, Crameri, R, Davies, J M, Douladiris, N, Ebisawa, M, EIgenmann, P A, Fernandez-Rivas, M, Ferreira, F, Gadermaier, G, Glatz, M, Hamilton, R G, Hawranek, T, Hellings, P, Hoffmann-Sommergruber, K, Jakob, T, Jappe, U, Jutel, M, Kamath, S D, Knol, E F, Korosec, P, Kuehn, A, Lack, G, Lopata, A L, Mäkelä, M, Morisset, M, Niederberger, V, Nowak-Węgrzyn, A H, Papadopoulos, N G, Pastorello, E A, Pauli, G, Platts-Mills, T, Posa, D, Poulsen, L. K., Raulf, M, Sastre, J, Scala, E, Schmid, J M, Schmid-Grendelmeier, P, van Hage, M, van Ree, R, Vieths, S, Weber, R, Wickman, M, Muraro, A, and Ollert, M.

Abstract

The availability of allergen molecules ('components') from several protein families has advanced our understanding of immunoglobulin E (IgE)-mediated responses and enabled 'component-resolved diagnosis' (CRD). The European Academy of Allergy and Clinical Immunology (EAACI) Molecular Allergology User's Guide (MAUG) provides comprehensive information on important allergens and describes the diagnostic options using CRD. Part A of the EAACI MAUG introduces allergen molecules, families, composition of extracts, databases, and diagnostic IgE, skin, and basophil tests. Singleplex and multiplex IgE assays with components improve both sensitivity for low-abundance allergens and analytical specificity; IgE to individual allergens can yield information on clinical risks and distinguish cross-reactivity from true primary sensitization. Part B discusses the clinical and molecular aspects of IgE-mediated allergies to foods (including nuts, seeds, legumes, fruits, vegetables, cereal grains, milk, egg, meat, fish, and shellfish), inhalants (pollen, mold spores, mites, and animal dander), and Hymenoptera venom. Diagnostic algorithms and short case histories provide useful information for the clinical workup of allergic individuals targeted for CRD. Part C covers protein families containing ubiquitous, highly cross-reactive panallergens from plant (lipid transfer proteins, polcalcins, PR-10, profilins) and animal sources (lipocalins, parvalbumins, serum albumins, tropomyosins) and explains their diagnostic and clinical utility. Part D lists 100 important allergen molecules. In conclusion, IgE-mediated reactions and allergic diseases, including allergic rhinoconjunctivitis, asthma, food reactions, and insect sting reactions, are discussed from a novel molecular perspective. The EAACI MAUG documents the rapid progression of molecular allergology from basic research to its integration into clinical practice, a quantum leap in the management of allergic patients.

Published
2016

43. Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review

Author

Dhami, S, Nurmatov, U, Roberts, G, Pfaar, O, Muraro, A, Ansotegui, IJ, Calderon, M, Cingi, C, Demoly, P, Durham, S, Gerth van Wijk, Roy, Halken, S, Hamelmann, E, Hellings, P, Jacobsen, L, Knol, E, Linnemann, DL, Lin, S, Maggina, V, Oude-Elberink, H, Pajno, G, Panwankar, R, Pastorello, E, Pitsios, C, Rotiroti, G, Timmermans, F, Tsilochristou, O, Varga, EM, Wilkinson, J, Williams, A, Worm, M, Zhang, L, Sheikh, A (Aziz), Dhami, S, Nurmatov, U, Roberts, G, Pfaar, O, Muraro, A, Ansotegui, IJ, Calderon, M, Cingi, C, Demoly, P, Durham, S, Gerth van Wijk, Roy, Halken, S, Hamelmann, E, Hellings, P, Jacobsen, L, Knol, E, Linnemann, DL, Lin, S, Maggina, V, Oude-Elberink, H, Pajno, G, Panwankar, R, Pastorello, E, Pitsios, C, Rotiroti, G, Timmermans, F, Tsilochristou, O, Varga, EM, Wilkinson, J, Williams, A, Worm, M, Zhang, L, and Sheikh, A (Aziz)

Published
2016

44. Large scale genotype-phenotype analyses indicate that novel prognostic tools are required for families with facioscapulohumeral muscular dystrophy

Author

Ricci, G, Scionti, I, Sera, F, Govi, M, D'Amico, R, Frambolli, I, Mele, F, Filosto, M, Vercelli, L, Ruggiero, L, Berardinelli, A, Angelini, C, Antonini, G, Bucci, E, Cao, M, Daolio, J, Di Muzio, A, Di Leo, R, Galluzzi, G, Iannaccone, E, Maggi, L, Maruotti, V, Moggio, M, Mongini, T, Morandi, L, Nikolic, A, Pastorello, E, Ricci, Enzo, Rodolico, C, Santoro, L, Servida, M, Siciliano, G, Tomelleri, G, Tupler, R., Ricci, Enzo (ORCID:0000-0003-3092-3597), Ricci, G, Scionti, I, Sera, F, Govi, M, D'Amico, R, Frambolli, I, Mele, F, Filosto, M, Vercelli, L, Ruggiero, L, Berardinelli, A, Angelini, C, Antonini, G, Bucci, E, Cao, M, Daolio, J, Di Muzio, A, Di Leo, R, Galluzzi, G, Iannaccone, E, Maggi, L, Maruotti, V, Moggio, M, Mongini, T, Morandi, L, Nikolic, A, Pastorello, E, Ricci, Enzo, Rodolico, C, Santoro, L, Servida, M, Siciliano, G, Tomelleri, G, Tupler, R., and Ricci, Enzo (ORCID:0000-0003-3092-3597)

Abstract

Facioscapulohumeral muscular dystrophy has been genetically linked to reduced numbers (≤ 8) of D4Z4 repeats at 4q35 combined with 4A(159/161/168) DUX4 polyadenylation signal haplotype. However, we have recently reported that 1.3% of healthy individuals carry this molecular signature and 19% of subjects affected by facioscapulohumeral muscular dystrophy do not carry alleles with eight or fewer D4Z4 repeats. Therefore, prognosis for subjects carrying or at risk of carrying D4Z4 reduced alleles has become more complicated. To test for additional prognostic factors, we measured the degree of motor impairment in a large group of patients affected by facioscapulohumeral muscular dystrophy and their relatives who are carrying D4Z4 reduced alleles. The clinical expression of motor impairment was assessed in 530 subjects, 163 probands and 367 relatives, from 176 unrelated families according to a standardized clinical score. The associations between clinical severity and size of D4Z4 allele, degree of kinship, gender, age and 4q haplotype were evaluated. Overall, 32.2% of relatives did not display any muscle functional impairment. This phenotype was influenced by the degree of relation with proband, because 47.1% of second- through fifth-degree relatives were unaffected, whereas only 27.5% of first-degree family members did not show motor impairment. The estimated risk of developing motor impairment by age 50 for relatives carrying a D4Z4 reduced allele with 1-3 repeats or 4-8 repeats was 88.7% and 55%, respectively. Male relatives had a mean score significantly higher than females (5.4 versus 4.0, P = 0.003). No 4q haplotype was exclusively associated with the presence of disease. In 13% of families in which D4Z4 alleles with 4-8 repeats segregate, the diagnosis of facioscapulohumeral muscular dystrophy was reported only in one generation. In conclusion, this large-scale analysis provides further information that should be taken into account when counselling families in whic

Published
2013

45. A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis

Author

Cristallo, A, Schroeder, J, Citterio, A, Santori, G, Ferrioli, G, Rossi, U, Bertani, G, Cassano, S, Gottardi, P, Ceschini, N, Barocci, F, Ribizzi, G, Cutrupi, V, Cairoli, R, Rapisarda, V, Pastorello, E, Barocci, S, Cristallo AF, Schroeder J, Citterio A, Santori G, Ferrioli GM, Rossi U, Bertani G, Cassano S, Gottardi P, Ceschini N, Barocci F, Ribizzi G, Cutrupi V, Cairoli R, Rapisarda V, Pastorello EA, Barocci S, Cristallo, A, Schroeder, J, Citterio, A, Santori, G, Ferrioli, G, Rossi, U, Bertani, G, Cassano, S, Gottardi, P, Ceschini, N, Barocci, F, Ribizzi, G, Cutrupi, V, Cairoli, R, Rapisarda, V, Pastorello, E, Barocci, S, Cristallo AF, Schroeder J, Citterio A, Santori G, Ferrioli GM, Rossi U, Bertani G, Cassano S, Gottardi P, Ceschini N, Barocci F, Ribizzi G, Cutrupi V, Cairoli R, Rapisarda V, Pastorello EA, and Barocci S

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are represented by rare but life-threatening cutaneous adverse reactions to different drugs. Previous studies have found that in a Han Chinese population from Taiwan and other Asian Countries, a strong genetic association between HLA-class I alleles (B*15:02, B*58:01) and SJS and TEN was induced by carbamazepine and allopurinol, respectively. To identify genetic markers that covered the MHC region, we carried out a case-control association enrolling 20 Caucasian patients with SJS/TEN. Our patient series included 10 cases related to paracetamol, 7 to allopurinol and 3 to different drugs (plaquenil, itraconazol, nabumetone). Healthy controls were represented by 115 Caucasian bone marrow or stem cell donors. The HLA-A*, B*, C*, DRB1*, DQB1*, DQA1* and DPB1* genotyping were determined. The frequencies of HLA-A*33:03 as well as C*03:02 and C*08:01 were significantly higher in SJS/TEN patient subgroup showing allopurinol drug-induced severe cutaneous adverse reactions (SCAR) as compared to controls (28.6% vs 0%, P=0.00002, Pc=0.0011; 28.6% vs 0%, P=0.00002, Pc=0.001; 28.6% vs 0%, P=0.00002, Pc=0.001, respectively). In the same subgroup the frequencies of B*58:01, DRB1*15:02 and DRB1*13:02 alleles, although considerably higher than in control group (42.8% vs 5.2%, P=0.003; 28.6% vs 1.7%, P=0.005; 28.6% vs 3.5%, P=0.037, respectively), appeared no more statistically different after P correction (Pc=0.248; Pc=0.29; Pc=1.00, respectively). In addition, in 10 of the 20 SJS/TEN patient subgroup with paracetamol-induced SCAR no statistically significant association with HLA alleles could be found. However, in the same SJS/TEN patient subgroup showing allopurinol drug-induced SCAR, haplotype analysis indicated that B*58:01, DRB1*13:02 and DRB1*15:02 alleles, that in a single allele analysis lost statistical significance after P correction, may still confer susceptibility, because the B*58:01-DRB1*13:02 and DRB1*1

Published
2011

46. Searching for allergens in maize kernels via proteomic tools

Author

Fasoli, Elisa, Pastorello, E. A., Farioli, L, Scibilia, J, Aldini, G, Carini, M, Marocco, Adriano, Boschetti, E, Righetti, Pier Giorgio, Marocco, Adriano (ORCID:0000-0001-5378-5591), Fasoli, Elisa, Pastorello, E. A., Farioli, L, Scibilia, J, Aldini, G, Carini, M, Marocco, Adriano, Boschetti, E, Righetti, Pier Giorgio, and Marocco, Adriano (ORCID:0000-0001-5378-5591)

Abstract

Up to the present, only one major allergen had been univocally identified by chemical analysis (N-terminal sequencing) in the salt-extractable (cytoplasmic) protein fraction of maize kernels (Zea mays): the lipid transfer protein (Pastorello et al., Allergy Clin. Immunol. 2000;106:744–751). In the present study, two-dimensional maps of kernel flour have been set up, the proteins transferred to nitrocellulose membranes and confronted with sera of various patients allergic to maize proteins. Via spot excision and Orbitrap mass analysis, the following new allergens have been identified: vicilin, globulin-2, 50 kDa gamma-zein, endochitinase, thioredoxin and trypsin inhibitor. Vicilin was found to be composed of a string of six spots, all of them allergenic; also globulin-2 was composed of a string of five spots, exhibiting equivalent allergenicity. The 50 kDa gamma-zein, found here in the maize flour soluble fraction, is identical to the 50 kDa allergen reported by Pasini et al. (Allergy 2002; 57:98–106), but present in the insoluble fraction and solubilized via -S-S- reducing agents. However, the form here described might be a truncated species, since it exhibits an apparent Mr, in SDS-PAGE, of ca. 35 kDa. The homology of three of them (vicilin, globulin-2 and thioredoxin) with other vegetable systems has been investigated via BLAST analysis, the ones with highest homology belonging to rice, wheat and barley. The present data add a non-negligible amount of previously unreported allergens to the scanty panorama of maize proteins.

Published
2009

47. Hazelnut allergy:a double-blind, placebo-controlled food challenge multicenter study

Author

Ortolani, C, Ballmer-Weber, B K, Hansen, K S, Ispano, M, Wüthrich, B, Bindslev-Jensen, C, Ansaloni, R, Vannucci, L, Pravettoni, V, Scibilia, J, Poulsen, L K, Pastorello, E A, Ortolani, C, Ballmer-Weber, B K, Hansen, K S, Ispano, M, Wüthrich, B, Bindslev-Jensen, C, Ansaloni, R, Vannucci, L, Pravettoni, V, Scibilia, J, Poulsen, L K, and Pastorello, E A

Abstract

BACKGROUND: Tree nuts are a common cause of food allergy in Europe. However, few studies deal with real food allergy to hazelnuts in subjects believed to be allergic to this food.OBJECTIVE: We sought to select subjects with a history of allergic reactions on ingestion of hazelnut and determine how many of these have true allergy by means of the double-blind, placebo-controlled food challenge (DBPCFC).METHODS: Eighty-six subjects with a history of symptoms after hazelnut ingestion were recruited from 3 allergy centers (Milan, Zurich, and Copenhagen). All subjects underwent skin prick tests (SPTs) with aeroallergens and hazelnut, as well as having their specific hazelnut IgE levels determined. Diagnosis of clinical relevant food allergy was made on the basis of the DBPCFC.RESULTS: Sixty-seven (77.9%) of 86 subjects had a positive DBPCFC result; 8 were placebo responders, and 11 were nonresponders. Of the 11 nonresponders, 4 had positive open-challenge test results. Of the DBPCFC-positive subjects, 87% also had positive skin test responses to birch pollen extract. Specific IgE determination for hazelnut (positive CAP response >/=0.7 kU/L [ie, class 2]) showed a sensitivity of 0.75, a positive predictive value (PPV) of 0.92, a specificity of 0.16, and a negative predictive value (NPV) of 0.05. Skin tests with commercial hazelnut extract produced a sensitivity of 0.89, a PPV of 0.92, a specificity of 0.05, and an NPV of 0.05. Skin tests with natural food produced a sensitivity of 0.88, a PPV of 0.94, a specificity of 0.27, and an NPV of 0.15.CONCLUSION: This study shows that hazelnut is an allergenic source that can cause real food allergy, as confirmed by DBPCFC. Skin and IgE tests demonstrated reasonable sensitivity and PPV but a very low specificity and NPV, thus implying that these should not be used to validate the diagnosis of food allergy to hazelnut.

Published
2000

48. 5-grass pollen tablets achieve disease control in patients with seasonal allergic rhinitis unresponsive to drugs: a real-life study

Author

Pastorello EA, Losappio L, Milani S, Manzotti G, Fanelli V, Pravettoni V, Agostinis F, D'Arcais AF, Dell'Albani I, Puccinelli P, Incorvaia C, and Frati F

Subjects
Immunologic diseases. Allergy, RC581-607
Abstract

Elide Anna Pastorello,1 Laura Losappio,1 Stefania Milani,2 Giuseppina Manzotti,3 Valentina Fanelli,4 Valerio Pravettoni,5 Fabio Agostinis,6 Alberto Flores D’Arcais,7 Ilaria Dell'Albani,8 Paola Puccinelli,9 Cristoforo Incorvaia,10 Franco Frati81Allergy and Immunology Department, Niguarda Hospital, Milan, 2Allergy Department, San Marco General Hospital, Bergamo, 3Allergy Department, Treviglio Hospital, Bergamo, 4Allergy Department, Italian Institute for Auxology, Milan, 5Clinical Allergy and Immunology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, 6Department of Pediatrics, Riuniti Hospital, Bergamo, 7Department of Pediatrics, Legnano Hospital, Milan, 8Medical and Scientific Department, Stallergenes Italy, Milan, 9Regulatory Department, Stallergenes Italy, Milan, 10Allergy/Pulmonary Rehabilitation, ICP Hospital, Milan, ItalyBackground: An important subpopulation in allergic rhinitis is represented by patients with severe form of disease that is not responsive to drug treatment. It has been reported that grass pollen subcutaneous immunotherapy is effective in drug-resistant patients. In a real-life study, we evaluated the efficacy of 5-grass pollen tablets in patients with grass pollen-induced allergic rhinitis not responsive to drug therapy.Methods: We carried out this multicenter observational study in adults and adolescents with grass-induced allergic rhinitis not responsive to drug therapy who were treated for a year with 5-grass pollen tablets. Clinical data collected before and after sublingual immunotherapy (SLIT) included Allergic Rhinitis and its Impact on Asthma (ARIA) classification of allergic rhinitis, response to therapy, and patient satisfaction.Results: Forty-seven patients entered the study. By ARIA classification, three patients had moderate to severe intermittent allergic rhinitis, ten had mild persistent allergic rhinitis, and 34 had moderate to severe persistent allergic rhinitis. There were no cases of mild intermittent allergic rhinitis before SLIT. After SLIT, 33 patients had mild intermittent allergic rhinitis, none had moderate to severe intermittent allergic rhinitis, seven had mild persistent allergic rhinitis, and seven had moderate to severe persistent allergic rhinitis. The mean medication score decreased from 4.2±1.3 before to 2.4±2.0 after SLIT (P

Published
2013

49. A multicentre controlled trial of terfenadine, dexchlorpheniramine, and placebo in allergic rhinitis

Author

Melillo, G., D Amato, G., Zanussi, C., Ortolani, C., Pastorello, E., Loy, M., Di Tucci, A., Locci, F., Del Giacco, G. S., Lenzini, L., Piersante Sestini, and Rottoli, P.

Subjects
Adult, Male, Aging, Chlorpheniramine, Clinical Trials as Topic, Adolescent, Middle Aged, drug therapy, adverse effects/therapeutic use, Sex Factors, Double-Blind Method, Histamine H1 Antagonists, Respiratory Hypersensitivity, Adolescent, Adult, Aging, Benzhydryl Compounds, adverse effects/therapeutic use, Chlorpheniramine, adverse effects/therapeutic use, Clinical Trials as Topic, Double-Blind Method, Female, Histamine H1 Antagonists, adverse effects/therapeutic use, Humans, Male, Middle Aged, Respiratory Hypersensitivity, drug therapy, Rhinitis, drug therapy, Sex Factors, Terfenadine, Humans, Female, Terfenadine, Benzhydryl Compounds, Rhinitis

Catalog

Books, media, physical & digital resources
See catalog results